Correlation of peripheral blood OX40+ (CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation

Blood

Volumn 98, Issue 10, 2001, Pages 3162-3164

  Kotani, Ai ^a   Ishikawa, Takayuki ^a   Matsumura, Yumi ^a   Ichinohe, Tatsuo ^a   Ohno, Hitoshi ^a   Hori, Toshiyuki ^a   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD69 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ALLOGRAFT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LABORATORY DIAGNOSIS; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 0035892124     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.10.3162     Document Type: Article

References (18)

1. Gaziev D, Galimberti M, Lucarelli J, Polchi P. Chronic graft-versus-host disease: is there an alternative to the conventional treatment? Bone Marrow Transplant. 2000;25:689-696.
2. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-674.
3. Kunitomi A, Hori T, Imura A, Uchiyama T. Vascular endothelial cells provide T cells with costimulatory signals via the OX40/gp34 system. J Leukoc Biol. 2000;68:111-118.
4. Tittle TV, Weinberg AD, Steinkeler CN, Mazziarz RT. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Blood. 1997;89:4652-4658.
5. Durie F, Fanslow WC, Zappone J, at el. Conversion of chronic graft-versus-host disease to that of acute phenotype using in vivo administration of an antibody to OX40 (abstract). FASEB J. 1996;10:1435.
6. Tsukada N, Akiba H, Kobata T, Aizawa Y, Yagita H, Okumura K. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood. 2000;95:2434-2439.
7. Stuber E, Von Freier A, Marinescu D, Folsch UR. Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease. Gastroenterology. 1998;115:1205-1215.
8. Weinberg AD, Wallin JJ, Jones RE, et al. Target organ specific upregulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with EAE. J Immunol. 1994;152:4712-4721.
9. Weinberg AD, Bourdette DN, Sullivan TJ, et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med. 1996;2:183-189.
10. Higgins LM, MacDonald SA, Whittle N, Crockett N, Shields JG, MacDonald TT. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol. 1999;162:486-493.
11. Murata K, Ishii N, Takano H, et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med. 2000;191:365-374.
12. Imura A, Hori T, Imada K, et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med. 1996;183:2185-2195.
13. Stuber E, Bushenfeld A, Luttges J, von Freier A, Arendt T, Folsch UR. The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis). Eur J Clin Invest. 2000;30:594-599.
14. Aten J, Roos J, Classen N, et al. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol. 2000;11:1426-1438.
15. Yoshioka T, Nakajima A, Akiba H, et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol. 2000;30:2815-2823.
16. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000;60:5514-5521.
17. Gadisseur APA, Gratama JW, Lamers C, van Esser JWJ, Bolhuis RLA, Cornelissen JJ. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 1999;23:1013-1017.
18. Deeg HJ, Klingemann HG, Phillips GL, Van Zant G. A Guide to Blood and Marrow Transplantation. Berlin, Germany: Springer-Verlag; 1999.